https://orcid.org/0000-0001-9274-2551
References
- Barber DL, Sakai S, Kudchadkar RR, Fling SP, Day TA, Vergara JA, Ashkin D, Cheng JH, Lundgren LM, Raabe VN, et al. Tuberculosis following PD-1 blockade for cancer immunotherapy. Sci Transl Med. 2019;11:11. doi:10.1126/scitranslmed.aat2702.
- Chorti E, Kanaki T, Zimmer L, Hadaschik E, Ugurel S, Gratsias E, Roesch A, Bonella F, Wessendorf TE, Wälscher J, et al. Drug-induced sarcoidosis-like reaction in adjuvant immunotherapy: increased rate and mimicker of metastasis. Eur J Cancer. 2020;131:18–26. doi:10.1016/j.ejca.2020.02.024.
- Lazar-Molnar E, Chen B, Sweeney KA, Wang EJ, Liu W, Lin J, Porcelli SA, Almo SC, Nathenson SG, Jacobs WR, et al. Programmed death-1 (PD-1)-deficient mice are extraordinarily sensitive to tuberculosis. Proc Natl Acad Sci U S A. 2010;107(30):13402–07. doi:10.1073/pnas.1007394107.
- Molloy A, Laochumroonvorapong P, Kaplan G. Apoptosis, but not necrosis, of infected monocytes is coupled with killing of intracellular bacillus Calmette-Guerin. J Exp Med. 1994;180:1499–509. doi:10.1084/jem.180.4.1499.
- Suarez GV, CDC MG, Vecchione MB, Trifone CA, Marín Franco JL, Genoula M, Moraña EJ, Balboa L, Quiroga MF. PD-1/PD-L1 pathway modulates macrophage susceptibility to mycobacterium tuberculosis specific CD8(+) T cell induced death. Sci Rep. 2019;9:187. doi:10.1038/s41598-018-36403-2.